Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 16,083 | 18,021 | 22,452 | 27,700 | 11,650 |
| Receivables | 40 | 90 | 27 | 27 | 97 |
| TOTAL | $16,758 | $18,410 | $23,149 | $28,121 | $12,193 |
| Non-Current Assets | |||||
| PPE Net | 247 | 268 | 295 | 320 | 338 |
| Intangibles | 411 | 421 | 431 | 442 | 452 |
| TOTAL | $657 | $689 | $727 | $761 | $790 |
| Total Assets | $17,415 | $19,099 | $23,875 | $28,883 | $12,984 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 887 | 316 | 2,002 | 1,050 | 1,697 |
| Accrued Expenses | 1,642 | 1,639 | 892 | 820 | 841 |
| Other current liabilities | 6,823 | 6,878 | 6,732 | 8,070 | N/A |
| TOTAL | $9,704 | $9,045 | $10,217 | $10,250 | $2,866 |
| Non-Current Liabilities | |||||
| TOTAL | $152 | $175 | $197 | $219 | $241 |
| Total Liabilities | $9,856 | $9,220 | $10,414 | $10,469 | $3,107 |
| Shareholders' Equity | |||||
| Common Shares | 58,594 | 58,079 | 57,412 | 56,784 | 45,256 |
| Retained earnings | -65,242 | -60,480 | -55,771 | -49,831 | -46,335 |
| Other shareholders' equity | 14,208 | 12,280 | 11,820 | 11,460 | 10,955 |
| TOTAL | $7,559 | $9,879 | $13,461 | $18,413 | $9,877 |
| Total Liabilities And Equity | $17,415 | $19,099 | $23,875 | $28,883 | $12,984 |